Why carry out this study?
|
The 4CMenB vaccine (Bexsero, GSK) was developed to protect against invasive meningococcal disease (IMD) caused by serogroup B Neisseria meningitidis. As 4CMenB antigens are also commonly found in other meningococcal serogroups, 4CMenB may offer protection against non-B serogroups causing IMD. |
We investigated if 4CMenB vaccination can raise a functional immune response against non-B serogroup strains in adolescents, one of the populations most susceptible to meningococcal disease. |
What was learned from the study?
|
We showed that the antibodies induced by vaccination of adolescents with 4CMenB induce bactericidal killing against N. meningitidis C, W, and Y, by using a large panel of 147 non-B isolates representative of current IMD epidemiology. |
While 4CMenB was developed to protect against N. meningitidis serogroup B, the immune responses observed in sera from adolescents vaccinated with 4CMenB suggest protection against non-B serogroups as well. |
These results expand earlier findings and support previous evidence that 4CMenB vaccination may have the added value of cross-protection against prevalent IMD-causing N. meningitidis serogroup C, W, and Y strains. |
Digital Features
Introduction
Methods
Meningococcal Isolates: Euro-3 Panel and Brazilian Panel
Immunogenicity Assessment
Ethics
Results
hSBA titers | MenC | MenW | MenY | All | ||||
---|---|---|---|---|---|---|---|---|
Pre-vac | Post-vac | Pre-vac | Post-vac | Pre-vac | Post-vac | Pre-vac | Post-vac | |
Euro-3 panel | N = 76 | N = 28 | N = 23 | N = 127 | ||||
≥ 1:4 | 2 (2.6) | 40 (52.6) | 4 (14.3) | 20 (71.4) | 5 (21.7) | 15 (65.2) | 11 (8.7) | 75 (59.1) |
≥ 1:8 | 0 (0.0) | 33 (43.4) | 3 (10.7) | 20 (71.4) | 3 (13.0) | 15 (65.2) | 6 (4.7) | 68 (53.5) |
≥ 1:16 | 0 (0.0) | 28 (36.8) | 3 (10.7) | 20 (71.4) | 2 (8.7) | 14 (60.9) | 5 (3.9) | 62 (48.8) |
≥ 1:32 | 0 (0.0) | 25 (32.9) | 2 (7.1) | 19 (67.9) | 1 (4.3) | 9 (39.1) | 3 (2.4) | 53 (41.7) |
≥ 1:64 | 0 (0.0) | 23 (30.3) | 1 (3.6) | 15 (53.6) | 1 (4.3) | 6 (26.1) | 2 (1.6) | 44 (34.6) |
≥ 1:128 | 0 (0.0) | 17 (22.4) | 0 (0.0) | 12 (42.9) | 1 (4.3) | 2 (8.7) | 1 (0.8) | 31 (24.4) |
Brazilian panel | N = 4 | N = 7 | N = 9 | N = 20 | ||||
≥ 1:4 | 0 (0.0) | 4 (100) | 0 (0.0) | 6 (85.7) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 16 (80.0) |
≥ 1:8 | 0 (0.0) | 4 (100) | 0 (0.0) | 6 (85.7) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 16 (80.0) |
≥ 1:16 | 0 (0.0) | 4 (100) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 15 (75.0) |
≥ 1:32 | 0 (0.0) | 3 (75.0) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 14 (70.0) |
≥ 1:64 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 11 (55.0) |
≥ 1:128 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 4 (44.4) | 0 (0.0) | 9 (45.0) |